newsfilter
← Latest News
GlobeNewswire·

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer's disease patients planned for